News Archives - Page 3 of 1712

TuesdaySep 08, 2026 11:10 am

NetworkNewsBreaks – Roth Capital Partners Hosts and Sponsors Investor Events Through June 2027

Roth Capital Partners is scheduled to host and sponsor more than a dozen investor events from September 2026 through June 2027, including seven ROTH-hosted conferences focused on healthcare, nuclear technology, solar and storage, technology and other growth sectors. Upcoming hosted events include the 5th Annual ROTH Healthcare Opportunities Conference on Sept. 29 in New York, the inaugural ROTH Critical Mass in Emerging Nuclear Technology on Oct. 1 in New York, the 13th Annual ROTH Solar & Storage Symposium at RE+ from Nov. 16-18 in Las Vegas and the 15th Annual ROTH Technology Conference from Nov. 17-18 in New York. The…

TuesdaySep 08, 2026 9:50 am

NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Registers Phase II Ebola Trial for NV-387 Oral Gummies

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, announced that its phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (“DRC”) has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. The company previously received local regulatory approval from ACOREP to begin the trial and said NV-387 has been delivered to the clinical trial site in Ituri province, with first patient dosing anticipated within one to two weeks, barring outbreak-related impediments. The adaptive trial will begin with a…

TuesdaySep 08, 2026 9:30 am

NetworkNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) Sets Q4 Biotech Spin-Off as Company Sharpens Critical Minerals Focus

Greenland Mines (NASDAQ: GRML) announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company, including plans to spin off its biotechnology division in the fourth quarter of 2026. Nasdaq has formally approved the company application relating to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements. The company also completed its acquisition of the Sarfartoq project on Sept. 1 following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of…

TuesdaySep 08, 2026 9:20 am

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) was featured in BioMedWire editorial coverage highlighting FDA clearance of the company Investigational New Drug (“IND”) application to begin a randomized, double-blind, placebo-controlled phase 2 trial of Lucid-MS in people with multiple sclerosis (“MS”). Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (“PAD2”) and target demyelination rather than broadly suppressing the immune system. The editorial notes that Lucid-MS previously completed phase 1 testing in healthy volunteers, with the company reporting favorable…

TuesdaySep 08, 2026 9:10 am

NetworkNewsBreaks – Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Retains P&E Mining Consultants to Support Murdock Mountain Project

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising. Nevada Organic Phosphate (CSE: NOP; OTCQB: NOPFF), a B.C.-based organic sedimentary phosphate exploration company, retained P&E Mining Consultants Inc. to provide independent technical support for its wholly owned Murdock Mountain Property in Elko County, Nevada. P&E will support ongoing technical evaluation, geological modeling and staged de-risking of the sedimentary phosphate horizon, drawing on experience in geological interpretation, 3D modeling, Mineral Resource and Mineral Reserve Estimates, Preliminary Economic Assessments, Feasibility Studies and mine planning. P&E also has direct phosphate-sector experience involving projects for First…

TuesdaySep 08, 2026 9:00 am

NetworkNewsBreaks – MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Expands Lawson Natural Hydrogen System With Continued Drilling

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising. Figure 1: Drilling at Lawson 3 Well, Genesis Trend (Aug. 2026) MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) reported that ongoing commercial validation drilling at the Lawson Complex 1 in south-central Saskatchewan has triangulated a large Natural Hydrogen system following completion of the Lawson 3 well, while drilling at Lawson 4, more than 2 km west, has further expanded the system. Lawson 4 intersected what the company interprets as a significant deep crustal fault or conduit at 2,310.5 meters after recording the…

FridaySep 04, 2026 1:23 pm

NetworkNewsBreaks – AOM Capital Provides $3.8 Million Bridge Financing to Healthcare Company

AOM Capital has provided $3.8 million in bridge financing to a Northeastern U.S. healthcare company, providing near-term liquidity while the operator awaits payment on outstanding healthcare reimbursements. The short-term facility was structured around the company’s pending reimbursement stream, with AOM evaluating outstanding receivables, the expected reimbursement timeline and operating performance. The financing provides working capital to bridge the period between delivery of healthcare services and payment from third-party payors and expands AOM’s activity in healthcare and specialty finance, including bridge, receivables-backed and special-situation transactions. To view the full press release, visit https://nnw.fm/fFwhu About AOM Capital AOM Capital is a private investment and specialty bridge lending firm…

FridaySep 04, 2026 10:10 am

NetworkNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Expands Nanox.ARC Distribution in New England

Nanox (NASDAQ: NNOX), through its U.S.-based subsidiary Nanox Impact Inc., entered into a distribution agreement with Associated X-Ray Imaging Corp. to support deployment of the Nanox.ARC across New England. Under the agreement, Associated X-Ray Imaging will market, distribute and support the FDA-cleared, multisource 3D digital tomosynthesis system, leveraging its regional customer relationships and service infrastructure. The agreement expands Nanox’s U.S. channel partner network and is intended to increase access to the Nanox.ARC in outpatient and community-based clinical settings across targeted markets. To view the full press release, visit https://nnw.fm/ChGtd About Nanox Nanox (NASDAQ: NNOX) is focused on driving the world’s…

FridaySep 04, 2026 9:00 am

NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech (NASDAQ: VRXA) a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in…

ThursdaySep 03, 2026 12:20 pm

NetworkNewsBreaks – OS Therapies Inc. (NYSE American: OSTX) Heads to Moody Capital Conference Amid Major OST-HER2 Regulatory Push

OS Therapies (NYSE American: OSTX) announced its upcoming participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference taking place Sept. 9-10 in New York City, where OS Animal Health will participate and the company is expected to engage with investors and strategic partners. The conference comes as OS Therapies enters a potentially significant regulatory period for OST-HER2, its investigational therapy for fully resected pulmonary metastatic osteosarcoma. The company expects interim three-year overall survival data and key FDA and U.K. regulatory meetings in September, followed by potential RMAT and Rolling Review decisions, with final three-year data, a U.S.…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Breaks Categories: News